Edward Rudnic, PhD
David Snyder, MBA
Ann Lowe, MD
Donald Treacy, PhD
Dave Miller, PhD
Senior VP Chemistry
Chris Brough, PhD
Senior VP of Technical Operations
Beth Burnside, PhD
VP Regulatory Affairs
Raj Sheel, MBA
VP Strategy & Corporate Development
Justin Keen, PhD
VP Pharmaceutical Development
Board Of Directors
Mr. Kirkpatrick is the President, Biotechnologies of Research Corporation Technologies (RCT) in Tucson, Arizona, and serves on the company’s Board of Directors. Shaun oversees RCT’s investment portfolio and technology development and licensing activities in therapeutics, life science tools, and diagnostics. RCT’s investment and technology portfolio includes some of today’s landmark platforms, pharmaceuticals and diagnostics, including the anticancer drugs cisplatin and carboplatin, the PSA blood test for prostate cancer, the technetium-99-based imaging agents, the Pichia protein expression system and the anticonvulsant drug Vimpat®. Shaun received a master’s degree in international economics from the Johns Hopkins University School of Advanced International Studies and a bachelor’s degree in economics and ecology/evolutionary biology from the University of Arizona. Mr. Kirkpatrick serves on the boards of several companies in RCT’s venture investment portfolio and is also a board member of the Flinn Foundation in Phoenix, AZ and the Critical Path Institute in Tucson, AZ.
Mr. Mack retired as the Chairman and CEO of Cambrex Corp, a NYSE company focused on the life science industry. In addition to DisperSol, James serves on the Board of Research Corporation Technologies, a Tucson, AZ based company dedicated to funding new therapeutic and medical device commercialization. Prior to Cambrex, James was the VP of Specialty Chemicals at Olin Corp and the President of Chemicals Division of Sherwin-Williams. He received a BS in Chemical Engineering. from Michigan Technological University and an MBA from Western New England College. Mr. Mack and his wife, Lorna, divide their time between Westport, CT and Sarasota, FL. They have five children and six grandchildren.
Mr. Samberg is the Managing Director of Acadia Woods Partners, LLC, a New York based investment partnership that focuses primarily on early stage technology companies. Jeff lived in the San Francisco Bay Area for 15 years where he held a number of high-tech management roles, including VP of Corporate Strategy for PeopleSoft Inc, VP of Business Development for Wily Technology, and Entrepreneur in Residence for Greylock Partners. Jeff received his MBA from Stanford University’s Graduate School of Business and his BA with high honors in Economics from Princeton University.
Dr. Yaniv is a co-founder and former CEO of DisperSol. Prior to DisperSol, Gershon was the CEO of IntegriCo Composites, a plastic products manufacturer. Gershon also worked at Simula Inc (currently a BAE Systems company) for fifteen years, serving in various positions, including Director of Corporate R&D, and founder and President of the Automotive Safety Division (ASD). He is an engineer by training with a PhD in Composite Materials from The Technion, Israel Institute of Technology, and an Executive MBA from Arizona State University. Gershon is the inventor of 14 US and international patents.
Dr. Rudnic is the Chief Executive Officer and President of DisperSol Technologies. Prior to DisperSol, Ed served as the CEO of QRx Pharma. He was also the founder, Chairman, and CEO of MiddleBrook Pharmaceuticals. Prior to founding MiddleBrook, Ed was the Senior VP, Development and Technical Operations for Shire Laboratories and held management roles at Merck (Schering-Plough) and at Bristol Myers-Squibb (E.R. Squibb). He is the lead inventor or co-inventor of 54 issued U.S. patents and numerous related international patents. Dr. Rudnic holds a BS in Pharmacy, an MS in Pharmaceutics, and a PhD in Pharmaceutical Sciences from the University of Rhode Island.